Status
Conditions
Treatments
About
The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximately 200 patients with a minimum of 50% of patients in the US will be registered in the clinical investigation.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
General Inclusion Criteria
Subject must provide written informed consent prior to any study-specific procedures which are not considered standard of care at the site.
Subject must be at least 18 years of age.
Subject has evidence of symptomatic Chronic Limb-Threatening Ischemia (CLTI) with infrapopliteal lesions.
Anatomic Inclusion Criteria
Exclusion criteria
General Exclusion Criteria
Anatomic Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
200 participants in 1 patient group
Loading...
Central trial contact
Rebecca Maslow; Karine Ruster
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal